New drugs in the treatment of chronic myeloid leukaemia Novas drogas no tratamento da leucemia mielóide crônica
The introduction of the BCR-ABL kinase inhibitor, imatinib mesylate (Gleevec®, Novartis) led to significant changes in the treatment of chronic myeloid leukaemia (CML) patients. However, despite the impressive percentage of responding patients, some CML cases, particularly those in advanced phases o...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2008-06-01
|
Series: | Revista Brasileira de Hematologia e Hemoterapia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000800007 |